CSPC’s R&D is being conducted in China and America at the same time and a global collaborative open research and development system has been established. At present, CSPC has a biological research team led by 13 American high-level medical scientists. Based on the institute for biological studies in China, it research antibody drug development centers in California, Texas and New Jersey. In these American centers, it aims at screening and preliminary study of new targets for antibody drugs, cell line construction and technology development of antibody drugs, fixed-point coupling of antibodies and development of ADC drugs, while in domestic R&D centers it focuses at industrialization amplification, production and bispecific antibody studies.
CSPC DOPHEN Corporation is the first overseas R&D center in the US, located in Sacramento which is the capital of California. The center is near to San Francisco Bay Area, America's biotechnology industry cluster. The center was started to be built in 2011 and began to run formally in 2012 with total investment of more than $ 10 million and it occupies 2300 square meters for lab region.
Conjupro Biotherapeutics,Inc., a subsidiary of CSPC, is located in Princeton, New Jersey. It is a cooperation and exchange platform of commerce, technology and talents between CSPC and American pharmaceuticals industry.Moreover, it is devoted to be a research center for clinical study and drug registration in America. Meanwhile, it is in charge of foreign cooperation service and screening novel projects, seeking for new cooperation chances with research institutes and technology companies throughout the world.
AlaMab, another subsidiary of CSPC, is a newly built biotechnology laboratory in Texas, USA. It mainly conducts the screening and preliminary study of new targets for antibody drugs while the R&D center in New Jersey mainly carry on cell line construction and technology development of antibody drugs.
It has state-of-art domestic R&D environment and equipped with the most advanced equipment and facilities. It has two national key laboratories as “chiral medicine development” and “novel pharmaceutical formulations and excipients”.
The medicine registration team has rich experience, fully understands registration policy and grasps technical guidelines. They can flexibly use the policies and guidelines on the premise of legal compliance and guarantee the successful registration.
It has the first clinical team in China who completed from phase I to phase IV clinical studies of Class 1 new medicine. It has several clinical research centers at home and abroad.
The patent team is led by one of the most experienced patent agents in domestic pharmaceutical companies, provides solid patent protection for the R&D of new medicines.
It has a professional new product transformation team which is in charge of the pilot scale-up production of new products and handover of production process。 It ensures the stable production process and first-class quality of the developed products。
It has innovative medicine screening platforms staffed by 100+ people. It screens independently candidate medicines through CADD and pharmacological in vitro and in vivo studies. It has several domestic and foreign joint laboratories and studies early-stage medicine discovery.